FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560141783> ?p ?o ?g. }

• W2560141783 endingPage "364" @default.
• W2560141783 startingPage "356" @default.
• W2560141783 abstract "Objectives: Constipation is the most common GI symptom in patients with diabetes mellitus (DM). Importantly, patients with constipation have lower health-related quality of life than those without constipation. Effective therapies for constipation are limited and there is a paucity of data evaluating the treatment of constipation in diabetics. Methods: Diabetic patients with chronic idiopathic constipation (CIC) as defined by Rome III criteria were recruited from outpatient clinics at a tertiary-care center and a Veterans Administration Hospital. Demographic data, baseline stool patterns, and a constipation-specific quality of life survey (Patient Assessment of Constipation Quality of Life (PAC-QOL)) were obtained. Baseline colonic transit time (CTT) was evaluated utilizing the wireless motility capsule. Patients were randomized in a double-blind fashion to 48 mcg per day lubiprostone or placebo for 8 weeks. The primary end point measured was the difference in number of spontaneous bowel movements (SBMs) per week vs. baseline for each group at each week after initiation of therapy. Secondary end points included changes in CTT after 4 weeks of therapy, PAC-QOL after 8 weeks of therapy, and changes from baseline in associated gastrointestinal (GI) symptoms as well as need for rescue medication at 2, 4, and 8 weeks. Results: Seventy-six patients (mean age, 56.9±9.1 years, 62% females) were randomized. There were no significant differences between the two groups’ baseline data or demographics. During the 8-week treatment period, patients in the lubiprostone group experienced an average of 1.83±0.80 (P=0.02) more SBMs per week than those in the placebo group as compared with baseline. The duration of CTT at Week 4 was shorter by an average of 13 h compared with baseline in the lubiprostone group, and was prolonged by an average of 7 h compared with baseline in the placebo group, leading to a treatment effect of 20.3±7.3 h (P=0.006). PAC-QOL improved in both the groups; however, there was no significant difference between the groups. There was no difference in associated GI symptoms and need for rescue medication between the two groups after 8 weeks. There were no serious adverse events reported during the study. Conclusions: This study suggests that lubiprostone is a safe and effective treatment for increasing weekly SBMs and decreasing CTT in patients with DM and CIC." @default.
• W2560141783 created "2016-12-16" @default.
• W2560141783 creator A5007668194 @default.
• W2560141783 creator A5014424838 @default.
• W2560141783 creator A5027246538 @default.
• W2560141783 creator A5027894254 @default.
• W2560141783 creator A5057286267 @default.
• W2560141783 creator A5062352652 @default.
• W2560141783 creator A5071067883 @default.
• W2560141783 creator A5091361579 @default.
• W2560141783 date "2017-02-01" @default.
• W2560141783 modified "2023-10-14" @default.
• W2560141783 title "A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients" @default.
• W2560141783 cites W1486462492 @default.
• W2560141783 cites W1491518420 @default.
• W2560141783 cites W1542569637 @default.
• W2560141783 cites W1559093554 @default.
• W2560141783 cites W1607423153 @default.
• W2560141783 cites W1668885871 @default.
• W2560141783 cites W1966250447 @default.
• W2560141783 cites W1995874631 @default.
• W2560141783 cites W2001830981 @default.
• W2560141783 cites W2003147380 @default.
• W2560141783 cites W2016771502 @default.
• W2560141783 cites W2017963851 @default.
• W2560141783 cites W2041581988 @default.
• W2560141783 cites W2056918532 @default.
• W2560141783 cites W2062013642 @default.
• W2560141783 cites W2068252338 @default.
• W2560141783 cites W2097640407 @default.
• W2560141783 cites W2099768372 @default.
• W2560141783 cites W2104056805 @default.
• W2560141783 cites W2126490470 @default.
• W2560141783 cites W2156286274 @default.
• W2560141783 cites W2258033180 @default.
• W2560141783 cites W2403656612 @default.
• W2560141783 cites W4212798604 @default.
• W2560141783 cites W4244455779 @default.
• W2560141783 doi "https://doi.org/10.1038/ajg.2016.531" @default.
• W2560141783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27922028" @default.
• W2560141783 hasPublicationYear "2017" @default.
• W2560141783 type Work @default.
• W2560141783 sameAs 2560141783 @default.
• W2560141783 citedByCount "31" @default.
• W2560141783 countsByYear W25601417832017 @default.
• W2560141783 countsByYear W25601417832018 @default.
• W2560141783 countsByYear W25601417832019 @default.
• W2560141783 countsByYear W25601417832020 @default.
• W2560141783 countsByYear W25601417832021 @default.
• W2560141783 countsByYear W25601417832022 @default.
• W2560141783 countsByYear W25601417832023 @default.
• W2560141783 crossrefType "journal-article" @default.
• W2560141783 hasAuthorship W2560141783A5007668194 @default.
• W2560141783 hasAuthorship W2560141783A5014424838 @default.
• W2560141783 hasAuthorship W2560141783A5027246538 @default.
• W2560141783 hasAuthorship W2560141783A5027894254 @default.
• W2560141783 hasAuthorship W2560141783A5057286267 @default.
• W2560141783 hasAuthorship W2560141783A5062352652 @default.
• W2560141783 hasAuthorship W2560141783A5071067883 @default.
• W2560141783 hasAuthorship W2560141783A5091361579 @default.
• W2560141783 hasConcept C126322002 @default.
• W2560141783 hasConcept C134018914 @default.
• W2560141783 hasConcept C142724271 @default.
• W2560141783 hasConcept C159110408 @default.
• W2560141783 hasConcept C168563851 @default.
• W2560141783 hasConcept C1862650 @default.
• W2560141783 hasConcept C204787440 @default.
• W2560141783 hasConcept C27081682 @default.
• W2560141783 hasConcept C2779951463 @default.
• W2560141783 hasConcept C2781093762 @default.
• W2560141783 hasConcept C2781112942 @default.
• W2560141783 hasConcept C3017955636 @default.
• W2560141783 hasConcept C555293320 @default.
• W2560141783 hasConcept C71924100 @default.
• W2560141783 hasConcept C90924648 @default.
• W2560141783 hasConceptScore W2560141783C126322002 @default.
• W2560141783 hasConceptScore W2560141783C134018914 @default.
• W2560141783 hasConceptScore W2560141783C142724271 @default.
• W2560141783 hasConceptScore W2560141783C159110408 @default.
• W2560141783 hasConceptScore W2560141783C168563851 @default.
• W2560141783 hasConceptScore W2560141783C1862650 @default.
• W2560141783 hasConceptScore W2560141783C204787440 @default.
• W2560141783 hasConceptScore W2560141783C27081682 @default.
• W2560141783 hasConceptScore W2560141783C2779951463 @default.
• W2560141783 hasConceptScore W2560141783C2781093762 @default.
• W2560141783 hasConceptScore W2560141783C2781112942 @default.
• W2560141783 hasConceptScore W2560141783C3017955636 @default.
• W2560141783 hasConceptScore W2560141783C555293320 @default.
• W2560141783 hasConceptScore W2560141783C71924100 @default.
• W2560141783 hasConceptScore W2560141783C90924648 @default.
• W2560141783 hasIssue "2" @default.
• W2560141783 hasLocation W25601417831 @default.
• W2560141783 hasLocation W25601417832 @default.
• W2560141783 hasOpenAccess W2560141783 @default.
• W2560141783 hasPrimaryLocation W25601417831 @default.
• W2560141783 hasRelatedWork W1989334224 @default.
• W2560141783 hasRelatedWork W2071684431 @default.
• W2560141783 hasRelatedWork W2164738986 @default.

• next